Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings LimitedNASDAQ: RGC

Profile

Sector:

Healthcare

Country:

Hong Kong

IPO:

16 July 2021

Next earnings report:

20 June 2025

Last dividends:

N/A

Next dividends:

N/A
$78.08 M
-86%vs. 3y high
41%vs. sector
-vs. 3y high
-vs. sector
-69%vs. 3y high
92%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 22 Nov 2024 23:29:14 GMT
$6.00-$0.01(-0.17%)

Dividend

No data over the past 3 years
No data over the past 3 years
No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

RGC Latest News

RGC Resources, Inc. Raises Annual Dividend to $0.83 per Share
globenewswire.com22 November 2024 Sentiment: POSITIVE

ROANOKE, Va., Nov. 22, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO), at its meeting on November 22, 2024, declared a quarterly dividend of $0.2075 per share on the Company's common stock. The indicated annual dividend is $0.83 per share, a $0.03, or 3.8%, per share increase over the prior annual level. The Company has now increased the annual dividend 21 consecutive years. Paul Nester, CEO of RGC Resources, Inc., stated, “The Roanoke Gas utility continues to deliver solid operational and financial performance. Further, we are pleased that the MVP was completed in 2024 and now delivering affordable, reliable natural gas to Southwest Virginia. This dividend increase, our 21st annual increase, reflects our commitment to deliver long-term shareholder value.” The dividend will be paid on February 1, 2025 to shareholders of record on January 17, 2025. This is the Company's 323rd consecutive quarterly cash dividend.

RGC Resources, Inc. Reports 2024 Earnings
globenewswire.com13 November 2024 Sentiment: POSITIVE

ROANOKE, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $11,760,896, or $1.16 per share, for the fiscal year ended September 30, 2024, compared to $11,299,282, or $1.14 per share, for the fiscal year ended September 30, 2023. The increase reflected higher levels of earnings from the Company's investment in the Mountain Valley Pipeline (“MVP”) due to more AFUDC in fiscal 2024 prior to the pipeline being placed in service in June 2024. The lower cost of natural gas in 2024 reduced bills to customers and revenues for the Company, despite inflationary costs leading to higher tariffs. Interest expense also increased primarily due to higher interest rates.

RGC Resources, Inc. Declares Quarterly Dividend
globenewswire.com30 September 2024 Sentiment: POSITIVE

ROANOKE, Va., Sept. 30, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (NASDAQ: RGCO), at its meeting on September 30, 2024, declared a quarterly dividend of $0.20 per share on the Company's common stock. The dividend will be paid on November 1, 2024 to shareholders of record on October 18, 2024. This is the Company's 322nd consecutive quarterly cash dividend.

RGC Resources, Inc. Reports Third Quarter Earnings
globenewswire.com05 August 2024 Sentiment: NEGATIVE

ROANOKE, Va., Aug. 05, 2024 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $156,692, or $0.02 per share, for the third quarter ended June 30, 2024, compared to $686,816, or $0.07 per share, for the fiscal quarter ended June 30, 2023. The decline was the result of decreased operating income due to higher personnel and professional costs as well as persistent inflationary pressures across most areas compared to a year ago, along with lower noncash earnings from the Company's investment in the Mountain Valley Pipeline, LLC (“MVP”) as the pipeline transitioned from construction to gas transmission operations.

RGC Resources, Inc. Schedules Third Quarter 2024 Earnings Call
globenewswire.com26 July 2024 Sentiment: POSITIVE

ROANOKE, Va., July 26, 2024 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) will host its quarterly conference call and webcast to review the results of its fiscal third quarter 2024 on Wednesday, August 7, 2024 at 9:00 a.m. eastern time. Related presentation materials will be available before the call on the Company website on the Investor & Financial Information page at https://www.rgcresources.com/investor-financial-information/ .

What type of business is Regencell Bioscience Holdings Limited?

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

What sector is Regencell Bioscience Holdings Limited in?

Regencell Bioscience Holdings Limited is in the Healthcare sector

What industry is Regencell Bioscience Holdings Limited in?

Regencell Bioscience Holdings Limited is in the Drug Manufacturers - Specialty & Generic industry

What country is Regencell Bioscience Holdings Limited from?

Regencell Bioscience Holdings Limited is headquartered in Hong Kong

When did Regencell Bioscience Holdings Limited go public?

Regencell Bioscience Holdings Limited initial public offering (IPO) was on 16 July 2021

What is Regencell Bioscience Holdings Limited website?

https://www.regencellbioscience.com

Is Regencell Bioscience Holdings Limited in the S&P 500?

No, Regencell Bioscience Holdings Limited is not included in the S&P 500 index

Is Regencell Bioscience Holdings Limited in the NASDAQ 100?

No, Regencell Bioscience Holdings Limited is not included in the NASDAQ 100 index

Is Regencell Bioscience Holdings Limited in the Dow Jones?

No, Regencell Bioscience Holdings Limited is not included in the Dow Jones index

When was Regencell Bioscience Holdings Limited the previous earnings report?

No data

When does Regencell Bioscience Holdings Limited earnings report?

The next expected earnings date for Regencell Bioscience Holdings Limited is 20 June 2025